"The best or the worst" end up in product development partnerships by ProQuest

VIEWS: 4 PAGES: 3

Skeptics have questioned whether PDPs can escape conflicts of interest given that they often, de facto, subsidize industry to develop a drug or vaccine. Other concerns that have been raised include whether PDPs set excessive and untoward conditions on the distribution or use of a drug or vaccine in a recipient country; whether they unfairly impose long-term agreements to provide products at discounted prices (which some recipient countries say is aimed at preventing a local generic industry from being established); and whether, as they develop products, their industrial partners are becoming more aggressive in using intellectual property law to skirt the original goal of providing "reasonably priced" drugs and vaccines.First and foremost, they've "leveraged" in-kind contributions and even some monies from industry for infectious and neglected diseases, said Christopher J. Elias, president of the Program for Appropriate Technology in Health. By sharing the costs and risks of product development, a PDP can "incent companies that would otherwise sit on the sidelines.""When you look at how much has been spent and how many products, I mean, I think the latest is that something like 93 candidates are in development," she says. "That's vaccines, drugs and diagnostics. And that number changes every day. Instead of reducing that number, just that that's multiple tens of more than were in clinical testing 10 years ago. And even if you do the math and you say (US)$3 billion, for that many products, that's very good value for money."-Wayne Kondro, CMAJ

More Info
To top